...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk
【24h】

Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk

机译:患有BRCA1 / 2突变或家族性乳腺癌风险高的女性的最佳年龄开始采取预防措施

获取原文
获取原文并翻译 | 示例

摘要

Women from high-risk families consider preventive measures for breast cancer including screening. Guidelines on screening differ considerably regarding starting age. We investigated whether age at diagnosis in affected relatives is predictive for age at diagnosis. We analyzed the age of breast cancer detection of 1,304 first- and second-degree relatives of 314 BRCA1, 164 BRCA2 and 244 high-risk participants of the Dutch MRI-SCreening study. The within- and between-family variance in the relative's age at diagnosis was analyzed with a random effect linear regression model. We compared the starting age of screening based on risk-group (25 years for BRCA1, 30 years for BRCA2 and 35 years for familial risk), on family history, and on the model, which combines both. The findings were validated in 63 families from the UK-MARIBS study. Mean age at diagnosis in the relatives varied between families; 95% range of mean family ages was 35-55 in BRCA1-, 41-57 in BRCA2- and 44-60 in high-risk families. In all, 14% of the variance in age at diagnosis, in BRCA1 even 23%, was explained by family history, 7% by risk group. Determining start of screening based on the model and on risk-group gave similar results in terms of cancers missed and years of screening. The approach based on familial history only, missed more cancers and required more screening years in both the Dutch and the United Kingdom data sets. Age at breast cancer diagnosis is partly dependent on family history which may assist planning starting age for preventive measures. What's new? Our study shows, that beside risk group also age at diagnosis in family members is predictive for age at onset in BRCA1 and 2 mutation carriers and women with familial risk. 14% of the variance in age at diagnosis, and in BRCA1 even 23%, was explained by family history versus 7% by risk group. This may be taken into account when determining the starting age for screening or other preventive measures.
机译:高危家庭的妇女考虑对乳腺癌的预防措施,包括筛查。筛查指南在开始年龄方面存在很大差异。我们调查了患病亲属的诊断年龄是否可预测诊断年龄。我们分析了荷兰MRI-SCreening研究的314个BRCA1、164个BRCA2和244个高风险参与者的1,304个一级和二级亲属的乳腺癌检测年龄。使用随机效应线性回归模型分析诊断时亲属年龄的家庭内部和家庭之间的差异。我们根据风险组(BRCA1为25岁,BRCA2为30岁,家族风险为35岁),家族病史以及结合了两者的模型对筛查的起始年龄进行了比较。研究结果在UK-MARIBS研究的63个家庭中得到验证。亲属在诊断时的平均年龄因家庭而异;在高风险家庭中,BRCA1的平均家庭年龄的95%范围为35-55岁,BRCA2为41-57,44-60岁。总体而言,BRCA1诊断时年龄差异的14%,甚至23%,是由家族史解释的,风险组是7%。根据模型和风险组确定筛查的开始,在漏诊癌症和筛查年限方面得出了相似的结果。仅基于家族史的方法在荷兰和英国的数据集中漏诊了更多的癌症,并且需要更长的筛查年限。乳腺癌诊断的年龄部分取决于家族史,这可能有助于规划预防措施的起始年龄。什么是新的?我们的研究表明,除了风险组,家庭成员的诊断年龄也可以预测BRCA1和2个突变携带者以及有家族风险的妇女的发病年龄。诊断时年龄的差异为14%,而BRCA1中甚至为23%,由家族史解释,而风险组为7%。在确定筛查或其他预防措施的起始年龄时,可以考虑到这一点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号